Medpace (MEDP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this provider of outsourced clinical development services have returned -2.5% over the past month versus the Zacks S&P 500 composite's -0.3% change. The Zacks Medical Services industry, to which Medpace belongs, has lost 0.2% over this period. Now the key question is: Where could the stock be ...

April is known for being favorable to Wall Street investors. But this year, April ended on a disappointing note. A sticky inflation rate, a resilient labor market and a significant decline in the U.S. GDP growth rate dented market participants’ confidence in risky assets like equities.However, U.S. stock markets rebounded in early May as recently released economic data boosted market participants’ confidence in equities. A sharp decline in April job additions, a notable deterioration of the U.S. GDP growth ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Gro ...

Company Participants Max Smock - William Blair Eric Coldwell - Baird Jack Wallace - Guggenheim Partners Dan Leonard - UBS Justin Bowers - Deutsche Bank David Windley - Jefferies I would now like to introduce your host for today's conference, Lauren Morris, Medpace's Director of Investor Relations. You may begin. Before we begin, I would like to remind you that our remarks and responses to your questions during this teleconference may include forward-looking statements within the meaning of the Private Secur ...

| --- | --- | |-------|-------| | | | | | | | | | MAKING THE COMPLEX SEAMLESS A. Net Book-to-Bill: Net New Business Awards divided by Revenue, net. B. Backlog Conversion Rate: Revenue, net, for the quarter divided by beginning backlog. BACKLOG AND NEW AWARD TRENDS ($ in millions) KEY FINANCIAL TRENDS ° WITH ANDS Forward-Looking Statements Q1 2024 – KEY OPERATING HIGHLIGHTS MAKING THE COMPLEX SEAMLESS Backlog Conversion Rate 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 Ending Backlog and Est. NTM Backlog Conversi ...

Medpace (MEDP) came out with quarterly earnings of $3.20 per share, beating the Zacks Consensus Estimate of $2.45 per share. This compares to earnings of $2.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 30.61%. A quarter ago, it was expected that this provider of outsourced clinical development services would post earnings of $2.23 per share when it actually produced earnings of $2.46, delivering a surprise of 10.31%.Over ...

David Windley Thank you. One moment for our next question. And our next question comes from John Sourbeer with UBS. Your line is now open. Yeah. And we gave a lot of kind of interim metrics in the volatile period because I think everyone wants more insight into what's going on and everything we know and even though a lot of these metrics are difficult to decipher. So I -- we're trying to avoid kind of giving -- getting too much into the weeds, where we got before. But yes, just to give you an idea, they rem ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________________________ FORM 10-K ________________________________________________________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF TH ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------|-------|-------|-------|-------------------------|-------------------------------------|-------|-------|-------|--------------------|----------------------------| | ($ in millions) | | 2023 | | Fourth Quarter \n2022 | % Change | | 2023 | | Full Year \n2022 | % Change | | Revenue, net | | | | | $ 498.4 $ 394.1 26.5 % | | | | | $ 1,885.8 $ 1,460.0 29.2 % | | Net New Business Awards | | | | | $ 614.7 $ 485.1 26. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 10-Q ___________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 _________ ...